Synergistic interactions with PI3K inhibition that induce apoptosis.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 28561737.
- Also identified by DOI 10.7554/eLife.24523 and PMC identifier 5479695.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Activating mutations involving the PI3K pathway occur frequently in human cancers. However, PI3K inhibitors primarily induce cell cycle arrest, leaving a significant reservoir of tumor cells that may acquire or exhibit resistance. We searched for genes that are required for the survival of PI3K mutant cancer cells in the presence of PI3K inhibition by conducting a genome scale shRNA-based apoptosis screen in a <i>PIK3CA</i> mutant human breast cancer cell. We identified 5 genes (<i>PIM2, ZAK, TACC1, ZFR, ZNF565</i>) whose suppression induced cell death upon PI3K inhibition. We showed that small molecule inhibitors of the PIM2 and ZAK kinases synergize with PI3K inhibition. In addition, using a microscale implementable device to deliver either siRNAs or small molecule inhibitors in vivo, we showed that suppressing these 5 genes with PI3K inhibition induced tumor regression. These observations identify targets whose inhibition synergizes with PI3K inhibitors and nominate potential combination therapies involving PI3K inhibition.
Medical subject headings
- Apoptosis
- Drug Synergism
- Enzyme Inhibitors
- Phosphoinositide-3 Kinase Inhibitors
- Protein Kinases
- Protein Serine-Threonine Kinases
- Proto-Oncogene Proteins